Frankly we’re having a difficult time understanding why everyone is doing the happy dance for the results released by Medtronic this morning. In our humble opinion the results were nothing to write home to Mom about. Domestically sales continued to decline and grew only in the low single digits internationally. Keep in mind these results come with the introduction of the 770G and 780G, which is now at the FDA. Systems which are competing against the new “gold” standard of hybrid closed insulin delivery the Control IQ from Tandem who releases results tomorrow.
We hate to bring in those . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.